CLINICAL TRIAL: RITUXAN/BEAM VS BEXXAR/BEAM FOR DIFFUSE LARGE B CELL NON-HODGKI

临床试验：RITUXAN/BEAM VS BEXXAR/BEAM 用于弥漫性大 B 细胞非 HODGKI

• 批准号: 7950999
• 负责人: EDWARD David BALL
• 金额: $ 0.11万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950999
• 关键词: Acute Myelocytic Leukemia; B-Lymphocytes; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cytogenetics; Diffuse; Funding; Grant; Hematopoietic; Immune; Incidence; Infection; Institution; Mucositis; Recovery; Research; Research Personnel; Resources; Roche brand of rituximab; Secondary Myelodysplastic Syndrome; Source; Time; Transplantation; United States National Institutes of Health; Upper arm; iodine-131-tositumomab; mortality; reconstitution

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to compare PFS between the two transplant arms. Secondary objectives are to compare overall survival, time to progression, CR and PR proportion at Day 100, time to hematopoietic recovery, hematologic function, incidence of infection, maximum mucositis score by Day +21, immune reconstitution, treatment-related mortality, incidence of myelodysplastic syndrome (MDS), secondary acute myelogenous leukemia (AML), or abnormal cytogenetics between the two arms.

这个子项目是众多研究子项目之一